C3N-01413
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 62.16016427
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ee0e68bf-7fa0-4edc-a9df-30a63c2db34a | — | — | 0.877 |
| 2 | TCGA-L9-A444-01A-21R-A24H-07 | — | cohortA1 | 0.873 |
| 3 | TCGA-22-1005-01A-01R-0692-07 | — | cohortMD2 | 0.859 |
| 4 | TCGA-CF-A47V-01A-11R-A23W-07 | — | — | 0.859 |
| 5 | SRR12202445 | — | — | 0.858 |
| 6 | TCGA-55-8621-01A-11R-2403-07 | — | cohortA1 | 0.856 |
| 7 | SRR12202486 | — | — | 0.855 |
| 8 | TCGA-86-8671-01A-11R-2403-07 | — | cohortMD2 | 0.855 |
| 9 | C3N-03057 | — | cohortA1 | 0.854 |
| 10 | TCGA-44-2657-01A-01R-1107-07 | — | cohortA1 | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.090 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.050 | Inavolisib | — uncovered |
| MYOGENESIS | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.040 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.020 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |